Cargando…
A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-t...
Autores principales: | Estrada-Zuniga, Cynthia M., Cheng, Zi-Ming, Ethiraj, Purushoth, Guo, Qianjin, Gonzalez-Cantú, Hector, Adderley, Elaina, Lopez, Hector, Landry, Bethany N., Zainal, Abir, Aronin, Neil, Ding, Yanli, Wang, Xiaojing, Aguiar, Ricardo C.T., Dahia, Patricia L.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381411/ https://www.ncbi.nlm.nih.gov/pubmed/35858593 http://dx.doi.org/10.1016/j.xcrm.2022.100686 |
Ejemplares similares
-
TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation
por: Guo, Qianjin, et al.
Publicado: (2023) -
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020) -
Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022) -
Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022) -
Identification and characterization of RET fusions in advanced colorectal cancer
por: Le Rolle, Anne-France, et al.
Publicado: (2015)